RxDoctor Payments Data

Daniel le, MD

Internal Medicine · Houston, TXNPI 1386669513

Payments from drug & device makers

$538in general payments, 2019–2025

Across 13 payments — averaging $41.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bone Support Inc.$150
  • Stryker$142
  • World Class Technology Corporation$83
  • Novo Nordisk$54
  • Pacira Therapeutics, Inc.$29
  • AstraZeneca$24
  • plus $56 from 4 others

What the payments were for

  • Food & beverage$538100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$538 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$39,349
Medicare patients
70
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin52$42,860
JanuviaSitagliptin Phosphate25$42,607
VascepaIcosapent Ethyl43$36,793
FarxigaDapagliflozin Propanediol22$30,839
TradjentaLinagliptin29$28,085
EliquisApixaban17$22,133
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$17,912
RybelsusSemaglutide15$13,747
LinzessLinaclotide11$6,370
Diclofenac Sodium50$3,927
Famotidine113$2,597
Rosuvastatin Calcium138$1,468
Amlodipine Besylate187$1,459
Atorvastatin Calcium147$1,167
Clobetasol Propionate30$987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$19$70,94581 claims
AstraZenecaFarxiga, Breztri Aerosphere$24$48,75151 claims
Novo NordiskRybelsus$54$13,74715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →